�Medarex, Inc.
(Nasdaq: MEDX) announced that nine clinical abstracts for ipilimumab,
an investigational anti-CTLA-4 antibody, in melanoma ar scheduled to be
the subject of presentations at the thirty-third Congress of the European Society
for Medical Oncology (ESMO) being held September 12-16, 2008 in Stockholm.
Many of the following abstracts will include updated one-year selection data
from three Phase 2 studies (008, 022 and 007) in antecedently treated
patients with in advance metastatic melanoma:
Ipilimumab Presentations in Advanced Melanoma
-- "Efficacy and safety of patients with ripe melanoma treated with
ipilimumab with or without the addition of prophylactic budesonide"
(Abstract #783P) I. Ron - Poster presentation from 12:45 p.m. to 1:45 p.m.
local time on Saturday, September 13, 2008.
-- "Treatment guidelines for the management of immune-related adverse
events in patients treated with ipilimumab, an anti-CTLA4 therapy"
(Abstract #787P) K. Chin - Poster discussion from 12:45 p.m. to 1:45 p.m.
local time on Saturday, September 13, 2008.
-- "Ipilimumab-mediated patterns of response in patients with
pretreated, advanced melanoma" (Abstract #784P) K. Harmankaya - Poster
demonstration from 12:45 p.m. to 1:45 p.m. local fourth dimension on Saturday, September
13, 2008.
-- "Clinical activity of ipilimumab in patients with sophisticated melanoma
and brain metastases" (Abstract #786P) J. S. Weber - Poster display
from 12:45 p.m. to 1:45 p.m. local fourth dimension on Saturday, September 13, 2008.
-- "Ipilimumab 10 mg/kg initiation dosing promotes T-cell activating in
patients with advanced melanoma" (Abstract #785P) A. Hoos - Poster
display and treatment from 12:45 p.m. to 1:45 p.m. local time on
Saturday, September 13, 2008.
-- "Effect of dose on efficacy and safety in ipilimumab-treated
patients with advanced melanoma - results from a Phase 2, randomized,
dose-ranging study" (Abstract #769O) C. Lebbe - Oral presentation from 3:30
p.m. to 5:30 p.m. local time on Monday, September 15, 2008.
-- "Efficacy and base hit of treatment-naive and antecedently treated
patients with sophisticated melanoma receiving ipilimumab" (Abstract #778PD) R.
Ridolfi - Poster discussion from 12:30 p.m. to 1:30 p.m. local time on
Monday, September 15, 2008.
-- "Efficacy and safety of ipilimumab in patients with advanced
malignant melanoma who had progressed on one or more prior therapies: results from a
single-arm, multicenter study" (Abstract #776PD) M. Maio - Poster
discourse from 12:30 p.m. to 1:30 p.m. local time on Monday, September 15,
2008.
-- "Prolonged stable disease in ipilimumab-treated patients with
advanced melanoma world Health Organization have progressed on prior anticancer therapies"
(Abstract #768O) V. Chiarion Sileni - Oral presentation from 3:30 p.m. to
5:30 p.m. local time on Monday, September 15, 2008.
More information most the ESMO Congress whitethorn be institute at http://www.esmo.org.
About Medarex
Medarex is a biopharmaceutical company focused on the breakthrough,
development and potential commercialisation of fully human antibody-based
therapeutics to treat severe and debilitating diseases, including
cancer, kindling, autoimmune disorders and infective diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacture experience to generate, support and potentially commercialize
a broad range of in full human antibody product candidates for itself and its
partners. More than 40 of these therapeutic production candidates derived from
Medarex technology are in human clinical testing or let had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the subject of regulatory
applications for merchandising authorization. Medarex is committed to construction
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information around Medarex, visit
its site at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights ar reserved.
Medarex, Inc.
http://www.medarex.com
More info
Tuesday, 9 September 2008
Subscribe to:
Comments (Atom)